Lenalidomide for red blood cell transfusion dependent IPSS low- or intermediate-1-risk myelodysplastic syndromes

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.

Share/Save